Novavax
NVAX
#5752
Rank
โ‚น100.94 B
Marketcap
โ‚น621.18
Share price
0.73%
Change (1 day)
-19.11%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚น120.15 Billion

According to Novavax's latest financial reports the company's total liabilities are โ‚น120.15 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น187.38 B-10.48%
2023-12-31โ‚น209.32 B-12.55%
2022-12-31โ‚น239.37 B9.82%
2021-12-31โ‚น217.96 B211.99%
2020-12-31โ‚น69.86 B172.91%
2019-12-31โ‚น25.59 B-2.61%
2018-12-31โ‚น26.28 B1.84%
2017-12-31โ‚น25.81 B-5.01%
2016-12-31โ‚น27.17 B337.91%
2015-12-31โ‚น6.20 B111.07%
2014-12-31โ‚น2.93 B49.21%
2013-12-31โ‚น1.97 B62.79%
2012-12-31โ‚น1.21 B79.77%
2011-12-31โ‚น0.67 B-4.87%
2010-12-31โ‚น0.70 B-2.56%
2009-12-31โ‚น0.72 B-51.47%
2008-12-31โ‚น1.49 B35.1%
2007-12-31โ‚น1.10 B-10.28%
2006-12-31โ‚น1.23 B-21%
2005-12-31โ‚น1.56 B-19.29%
2004-12-31โ‚น1.93 B-11.79%
2003-12-31โ‚น2.19 B-7.39%
2002-12-31โ‚น2.37 B23.99%
2001-12-31โ‚น1.91 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Agenus
AGEN
โ‚น46.27 B-61.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น195.37 B 62.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚น78.97 B-34.27%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚น75.00 B-37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น6.156 T 5,023.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
โ‚น10.395 T 8,551.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น5.621 T 4,578.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
โ‚น0.11 B-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚น5.509 T 4,485.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
โ‚น4.50 B-96.25%๐Ÿ‡บ๐Ÿ‡ธ USA